HST Global, Inc. (HSTC)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5303.00 USD | 96.24% |
| 2022 | -141.03 Thousand USD | 3.21% |
| 2021 | -145.71 Thousand USD | 29.94% |
| 2020 | -207.97 Thousand USD | -37.23% |
| 2019 | -151.55 Thousand USD | -6.29% |
| 2018 | -142.58 Thousand USD | -10.24% |
| 2017 | -12.09 Thousand USD | 5.78% |
| 2016 | -137.27 Thousand USD | 14.23% |
| 2015 | -160.04 Thousand USD | -7.45% |
| 2014 | -148.95 Thousand USD | 5.33% |
| 2013 | -157.34 Thousand USD | 54.01% |
| 2012 | -342.15 Thousand USD | 0.46% |
| 2011 | -503.75 Thousand USD | 54.23% |
| 2010 | -751 Thousand USD | 42.9% |
| 2009 | -1.31 Million USD | 13.07% |
| 2008 | -1.51 Million USD | -954.36% |
| 2007 | -143.48 Thousand USD | 86.73% |
| 2006 | -1.57 Million USD | 6.64% |
| 2005 | -1.15 Million USD | -1699.28% |
| 2004 | -64.35 Thousand USD | 92.72% |
| 2003 | -884.05 Thousand USD | -652.74% |
| 2002 | -117.44 Thousand USD | -117.86% |
| 2001 | -381.91 Thousand USD | 149.07% |
| 2000 | -1.34 Million USD | -538.1% |
| 1999 | -210 Thousand USD | -111.29% |
| 1998 | 1.86 Million USD | 602.7% |
| 1997 | -370 Thousand USD | -146.25% |
| 1996 | -900 Thousand USD | 500.0% |
| 1995 | -700 Thousand USD | 66.67% |
| 1994 | -600 Thousand USD | -100.0% |
| 1993 | -300 Thousand USD | 70.0% |
| 1992 | -1 Million USD | -25.0% |
| 1991 | -800 Thousand USD | -260.0% |
| 1990 | 500 Thousand USD | 25.0% |
| 1989 | 400 Thousand USD | 500.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -16.56 Thousand USD | 49.35% |
| 2024 Q1 | -32.68 Thousand USD | -2193.89% |
| 2023 FY | - USD | 0.09% |
| 2023 Q1 | -38.07 Thousand USD | -10.08% |
| 2023 Q4 | -35.47 Thousand USD | -3.21% |
| 2023 Q3 | -34.36 Thousand USD | -4.18% |
| 2023 Q2 | -32.99 Thousand USD | 13.36% |
| 2022 Q4 | -34.58 Thousand USD | -0.0% |
| 2022 Q2 | -34.52 Thousand USD | 7.52% |
| 2022 Q1 | -37.33 Thousand USD | -7.9% |
| 2022 FY | - USD | 3.21% |
| 2022 Q3 | -34.58 Thousand USD | -0.17% |
| 2021 Q3 | -34.59 Thousand USD | 9.47% |
| 2021 Q4 | -34.59 Thousand USD | -0.0% |
| 2021 Q2 | -38.21 Thousand USD | 0.23% |
| 2021 FY | - USD | 29.94% |
| 2021 Q1 | -38.3 Thousand USD | 59.53% |
| 2020 Q3 | -34.68 Thousand USD | 20.86% |
| 2020 Q4 | -94.65 Thousand USD | -172.93% |
| 2020 Q1 | -34.81 Thousand USD | -36.65% |
| 2020 Q2 | -43.82 Thousand USD | -25.86% |
| 2020 FY | - USD | -37.23% |
| 2019 Q4 | -25.48 Thousand USD | 53.68% |
| 2019 Q3 | -55 Thousand USD | -58.26% |
| 2019 Q2 | -34.75 Thousand USD | 4.27% |
| 2019 Q1 | -36.3 Thousand USD | -4.88% |
| 2019 FY | - USD | -6.29% |
| 2018 Q4 | -34.61 Thousand USD | 0.06% |
| 2018 Q1 | -37.87 Thousand USD | -10.5% |
| 2018 Q3 | -34.63 Thousand USD | 2.31% |
| 2018 Q2 | -35.45 Thousand USD | 6.39% |
| 2018 FY | - USD | -10.24% |
| 2017 Q3 | -31.11 Thousand USD | 10.08% |
| 2017 Q4 | -34.27 Thousand USD | -10.17% |
| 2017 FY | - USD | 5.78% |
| 2017 Q1 | -53 Thousand USD | -53.39% |
| 2017 Q2 | -34.59 Thousand USD | 34.73% |
| 2016 Q2 | -35.65 Thousand USD | -6.35% |
| 2016 Q1 | -33.52 Thousand USD | 13.87% |
| 2016 Q3 | -33.54 Thousand USD | 5.9% |
| 2016 FY | - USD | 14.23% |
| 2016 Q4 | -34.55 Thousand USD | -3.02% |
| 2015 Q3 | -32.48 Thousand USD | 10.37% |
| 2015 FY | - USD | -7.45% |
| 2015 Q4 | -38.91 Thousand USD | -19.8% |
| 2015 Q1 | -52.39 Thousand USD | -48.35% |
| 2015 Q2 | -36.24 Thousand USD | 30.83% |
| 2014 FY | - USD | 5.33% |
| 2014 Q3 | -37.83 Thousand USD | 1.56% |
| 2014 Q2 | -38.43 Thousand USD | -2.89% |
| 2014 Q1 | -37.35 Thousand USD | -12.0% |
| 2014 Q4 | -35.32 Thousand USD | 6.64% |
| 2013 Q3 | -37.14 Thousand USD | 33.26% |
| 2013 FY | - USD | 54.01% |
| 2013 Q4 | -33.35 Thousand USD | 10.2% |
| 2013 Q2 | -55.65 Thousand USD | -78.42% |
| 2013 Q1 | -31.19 Thousand USD | 61.56% |
| 2012 Q3 | -83.03 Thousand USD | 17.61% |
| 2012 Q4 | -81.15 Thousand USD | 2.26% |
| 2012 Q2 | -100.77 Thousand USD | -30.56% |
| 2012 Q1 | -77.19 Thousand USD | 67.5% |
| 2012 FY | - USD | 0.46% |
| 2011 Q1 | -85.5 Thousand USD | -14.76% |
| 2011 Q2 | -98.84 Thousand USD | -15.59% |
| 2011 Q3 | -81.85 Thousand USD | 17.19% |
| 2011 Q4 | -237.54 Thousand USD | -190.19% |
| 2011 FY | - USD | 54.23% |
| 2010 Q4 | -74.51 Thousand USD | 52.03% |
| 2010 Q3 | -155.33 Thousand USD | 50.0% |
| 2010 Q2 | -310.65 Thousand USD | -38.68% |
| 2010 FY | - USD | 42.9% |
| 2010 Q1 | -224 Thousand USD | 29.56% |
| 2009 Q1 | -323.87 Thousand USD | -35.51% |
| 2009 FY | - USD | 13.07% |
| 2009 Q4 | -317.99 Thousand USD | -0.39% |
| 2009 Q3 | -316.76 Thousand USD | 11.14% |
| 2009 Q2 | -356.5 Thousand USD | -10.08% |
| 2008 Q3 | -434.31 Thousand USD | 39.69% |
| 2008 FY | - USD | -954.36% |
| 2008 Q2 | -720.08 Thousand USD | -881.8% |
| 2008 Q1 | -73.34 Thousand USD | -65.78% |
| 2008 Q4 | -239 Thousand USD | 44.97% |
| 2007 Q3 | -99.24 Thousand USD | -144.95% |
| 2007 Q1 | 2.51 Million USD | 200.74% |
| 2007 Q4 | -44.24 Thousand USD | 55.42% |
| 2007 Q2 | 220.78 Thousand USD | -91.23% |
| 2007 FY | - USD | 86.73% |
| 2006 Q1 | -89.17 Thousand USD | 92.05% |
| 2006 Q2 | -29.2 Thousand USD | 67.25% |
| 2006 Q4 | -2.49 Million USD | -418.91% |
| 2006 Q3 | 783.5 Thousand USD | 2782.87% |
| 2006 FY | - USD | 6.64% |
| 2005 Q4 | -1.12 Million USD | -542.47% |
| 2005 FY | - USD | -1699.28% |
| 2005 Q2 | -11.52 Thousand USD | -156.75% |
| 2005 Q3 | -174.52 Thousand USD | -1413.93% |
| 2005 Q1 | 20.31 Thousand USD | 167.91% |
| 2004 FY | - USD | 92.72% |
| 2004 Q4 | -29.91 Thousand USD | -56.68% |
| 2004 Q3 | -19.09 Thousand USD | -117.7% |
| 2004 Q2 | -8770.00 USD | -33.28% |
| 2004 Q1 | -6580.00 USD | 85.99% |
| 2003 Q1 | -149.23 Thousand USD | -136.52% |
| 2003 Q2 | -15 Thousand USD | 89.95% |
| 2003 Q3 | -672.84 Thousand USD | -4385.65% |
| 2003 Q4 | -46.97 Thousand USD | 93.02% |
| 2003 FY | - USD | -652.74% |
| 2002 Q4 | 408.59 Thousand USD | 213.25% |
| 2002 Q2 | -134.54 Thousand USD | -658.74% |
| 2002 Q1 | -17.73 Thousand USD | -159.11% |
| 2002 Q3 | -360.8 Thousand USD | -168.16% |
| 2002 FY | - USD | -117.86% |
| 2001 FY | - USD | 149.07% |
| 2001 Q4 | 29.99 Thousand USD | 103.37% |
| 2001 Q3 | -890 Thousand USD | -456.25% |
| 2001 Q2 | -160 Thousand USD | -300.0% |
| 2001 Q1 | -40 Thousand USD | 96.3% |
| 2000 Q4 | -1.08 Million USD | -460.0% |
| 2000 Q3 | 300 Thousand USD | 156.6% |
| 2000 Q2 | -530 Thousand USD | -1666.67% |
| 2000 Q1 | -30 Thousand USD | 82.35% |
| 2000 FY | - USD | -538.1% |
| 1999 Q3 | - USD | 100.0% |
| 1999 Q2 | -90 Thousand USD | -325.0% |
| 1999 Q4 | -170 Thousand USD | 0.0% |
| 1999 FY | - USD | -111.29% |
| 1999 Q1 | 40 Thousand USD | 114.29% |
| 1998 FY | - USD | 602.7% |
| 1998 Q4 | -280 Thousand USD | -187.5% |
| 1998 Q3 | 320 Thousand USD | -81.18% |
| 1998 Q2 | 1.7 Million USD | 1445.45% |
| 1998 Q1 | 110 Thousand USD | 115.49% |
| 1997 Q1 | -100 Thousand USD | 91.67% |
| 1997 Q4 | -710 Thousand USD | -273.68% |
| 1997 Q3 | -190 Thousand USD | -147.5% |
| 1997 FY | - USD | -146.25% |
| 1997 Q2 | 400 Thousand USD | 500.0% |
| 1996 Q3 | 200 Thousand USD | 100.0% |
| 1996 FY | - USD | 500.0% |
| 1996 Q1 | -200 Thousand USD | 87.5% |
| 1996 Q2 | 100 Thousand USD | 150.0% |
| 1996 Q4 | -1.2 Million USD | -700.0% |
| 1995 Q1 | 200 Thousand USD | 101.72% |
| 1995 Q4 | -400 Thousand USD | -433.33% |
| 1995 Q3 | -600 Thousand USD | 0.0% |
| 1995 Q2 | 200 Thousand USD | -250.0% |
| 1995 FY | - USD | 66.67% |
| 1994 Q4 | -11.6 Million USD | -390.0% |
| 1994 Q1 | 300 Thousand USD | 50.0% |
| 1994 FY | - USD | -100.0% |
| 1994 Q2 | -200 Thousand USD | -166.67% |
| 1994 Q3 | 4 Million USD | 2100.0% |
| 1993 Q2 | -200 Thousand USD | 0.0% |
| 1993 Q1 | -200 Thousand USD | 66.67% |
| 1993 FY | - USD | 70.0% |
| 1993 Q3 | -200 Thousand USD | 0.0% |
| 1993 Q4 | 200 Thousand USD | 200.0% |
| 1992 FY | - USD | -25.0% |
| 1992 Q1 | 100 Thousand USD | 125.0% |
| 1992 Q2 | -300 Thousand USD | -400.0% |
| 1992 Q3 | -200 Thousand USD | 33.33% |
| 1992 Q4 | -600 Thousand USD | -200.0% |
| 1991 Q4 | -400 Thousand USD | -100.0% |
| 1991 Q1 | 100 Thousand USD | -66.67% |
| 1991 FY | - USD | -233.33% |
| 1991 Q3 | -200 Thousand USD | 33.33% |
| 1991 Q2 | -300 Thousand USD | -400.0% |
| 1990 Q1 | -100 Thousand USD | 50.0% |
| 1990 Q2 | 200 Thousand USD | 300.0% |
| 1990 Q3 | -100 Thousand USD | -150.0% |
| 1990 Q4 | 300 Thousand USD | 400.0% |
| 1990 FY | - USD | 20.0% |
| 1989 Q4 | -200 Thousand USD | -200.0% |
| 1989 FY | - USD | 350.0% |
| 1989 Q1 | 1.6 Million USD | 141.03% |
| 1989 Q2 | 100 Thousand USD | -93.75% |
| 1989 Q3 | 200 Thousand USD | 100.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.993% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 99.911% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.992% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.969% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.006% |
| Mesoblast Limited | -62.38 Million USD | 99.992% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 99.655% |
| Genus plc | 73.7 Million USD | 100.007% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 99.92% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 99.85% |
| Marizyme, Inc. | -34.28 Million USD | 99.985% |
| ContraFect Corporation | -64.99 Million USD | 99.992% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.94% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 99.883% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 99.622% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 99.799% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 99.772% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 98.976% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.858% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.989% |
| EV Biologics, Inc. | -1.26 Million USD | 99.581% |
| Q BioMed Inc. | -617.62 Thousand USD | 99.141% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.148% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 99.161% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 99.768% |
| Biomind Labs Inc. | -1.03 Million USD | 99.487% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 100.054% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 99.926% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.961% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 99.643% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 78.788% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 99.863% |
| IMV Inc. | -35.52 Million USD | 99.985% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.967% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 99.788% |
| GB Sciences, Inc. | -1.41 Million USD | 99.627% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.945% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 92.861% |
| Enzolytics Inc. | -2.12 Million USD | 99.75% |
| Resverlogix Corp. | -11.74 Million USD | 99.955% |
| Affymax, Inc. | -14.29 Million USD | 99.963% |
| SYBLEU INC | -141.57 Thousand USD | 96.254% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 99.827% |
| argenx SE | -216.02 Million USD | 99.998% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.99% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 100.436% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 99.646% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 101.4% |
| AVAX Technologies, Inc. | -6.11 Million USD | 99.913% |
| Zenith Capital Corp. | -8.6 Million USD | 99.938% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.998% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 69.56% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 99.783% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 96.987% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.987% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 99.817% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 99.493% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 178.867% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 99.697% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 99.724% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.93% |
| ONE Bio Corp. | 13.61 Million USD | 100.039% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 97.072% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 99.742% |
| Agentix Corp. | -1.37 Million USD | 99.613% |
| LadRx Corporation | 412.28 Thousand USD | 101.286% |
| Cell Source, Inc. | -4.27 Million USD | 99.876% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 98.556% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.362% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 99.434% |
| NovAccess Global Inc. | -1.03 Million USD | 99.488% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.06% |
| Itoco Inc. | -1.86 Million USD | 99.716% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 98.603% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 99.525% |
| Kadimastem Ltd | -2.62 Million USD | 99.798% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 97.783% |
| CytoDyn Inc. | -18.02 Million USD | 99.971% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 93.29% |
| Mobile Lads Corp. | -2.24 Million USD | 99.763% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 56.636% |
| Qrons Inc. | -40.08 Thousand USD | 86.769% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 98.908% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 101.005% |
| Rebus Holdings, Inc. | -951 Thousand USD | 99.442% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 99.501% |
| International Stem Cell Corporation | 202 Thousand USD | 102.625% |
| Bioxytran, Inc. | -3.82 Million USD | 99.861% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 89.926% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 99.785% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.985% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | 88.216% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 99.806% |
| Neutra Corp. | -181.24 Thousand USD | 97.074% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.974% |
| PureTech Health plc | -11.62 Million USD | 99.954% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.974% |
| IXICO plc | -707 Thousand USD | 99.25% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.931% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.989% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 99.994% |